Over the past few years, a new class of injectable medications has changed the way obesity is treated. Two drugs—tirzepatide ...

Limited effectiveness, weight regain, and high prevalence of adverse events are the three key limitations of semaglutide ...

In an abrupt and surprising twist, the CEO of Ozempic-maker Novo Nordisk has been ousted from his position as the head of the ...

When treating obesity, semaglutide may be associated with a reduced fracture risk compared with sleeve gastrectomy.

For those preferring a drug-free approach to weight loss, research shows that certain nutrients and dietary strategies can ...

However, many on Wall Street believe that better days lie ahead for Novo Nordisk. Analysts expect this obesity drug stock to ...

The side effects of the two drugs combined include dizziness, abnormal sensations, altered taste, insomnia, constipation and ...

Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.

The benefit was seen as soon as 3 months. Investigators say there should be no delaying treatment for eligible patients.

Research on weight loss drugs like Ozempic shows varied results for mental health impacts, with some patients experiencing mood and personality changes.

A digital obesity clinic, Embla, is associated with 16.7% weight loss over 64 weeks, matching previous semaglutide trial ...

ORLANDO -- Fracture risk may be higher after bariatric surgery than after treatment with weight-loss drugs, propensity-score ...